CEL-SCI Corp CVM:NYSE American

Last Price$4.37AMEX Previous Close - Last Trade as of 6:30PM ET 7/06/22

Today's Change+0.20(4.80%)
Bid (Size)$3.02 (2)
Ask (Size)$4.76 (4)
Day Low / High$4.15 - 4.42
Volume256.7 K

View Biotechnology IndustryPeer Comparison as of 07/06/2022



Price: $4.37
Change: +0.20 (4.80%)
Volume: 256.7 K
6:30PM ET 7/06/2022

VistaGen Therapeutics Inc ( NASDAQ )

Price: $0.91
Change: +0.03 (3.84%)
Volume: 2.0 M
4:00PM ET 7/06/2022

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

XBiotech Inc ( NASDAQ )

Price: $5.88
Change: +0.09 (1.55%)
Volume: 59.0 K
4:00PM ET 7/06/2022

Personalis Inc ( NASDAQ )

Price: $3.70
Change: -0.03 (0.80%)
Volume: 513.3 K
4:00PM ET 7/06/2022

Read more news Recent News

--EF Hutton Initiates Cel-Sci With Buy Rating, $17 Price Target
1:42PM ET 4/08/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--EF Hutton Initiates Cel-Sci at Buy with $17 Price Target
11:02AM ET 4/07/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (CVM) CEL-SCI CORPORATION Posts Q1 Loss $-0.20
9:03AM ET 2/14/2022 MT Newswires


Insider Trends: Insider Buying Added to with Purchase of Cel-Sci Shares
10:46AM ET 7/07/2021 MT Newswires

Geert R Kersten, Director and CEO, purchased 25,000 shares of Cel-Sci (CVM) on Jul 06, 2021, for $200,000. After the Form 4 filing with the SEC, Kersten...

View all Commentary and Analysis

CEL-SCI: No Rush Here
12:22PM ET 2/24/2022 Seeking Alpha

CEL-SCI's Tough Road Ahead
12:43PM ET 8/20/2021 Seeking Alpha

CEL-SCI, Poised For Success, Is A Seriously Big Opportunity (Part II)
8:12PM ET 8/11/2021 Seeking Alpha

CEL-SCI: Pivotal Clinical Trial Results Point To Upside For Patients And Investors
1:25PM ET 7/14/2021 Seeking Alpha

Company Profile

Business DescriptionCEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA. View company web site for more details
Address8229 Boone Boulevard
Vienna, Virginia 22182
Number of EmployeesN/A
Recent SEC Filing07/05/20224
CEO, Chief Financial Officer, Treasurer & DirectorGeert R. Kersten
Secretary & Senior Vice President-OperationsPatricia B. Prichep
Chief Scientific OfficerEyal Talor
Vice President-Quality AssuranceWilliam Jones

Company Highlights

Price Open$4.15
Previous Close$4.37
52 Week Range$2.49 - 12.90
Market Capitalization$189.3 M
Shares Outstanding43.3 M
SectorHealth Technology
Next Earnings Announcement08/15/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.87
Beta vs. S&P 500N/A
Revenue$476.6 K
Net Profit MarginN/A
Return on Equity-67.20%

Analyst Ratings as of 04/06/2022

Consensus RecommendationConsensus Icon
Powered by Factset